BioInformant

Your Global Leader in Stem Cell Market Research

Home » Coronavirus (COVID-19) » Page 2

Biotech Investing: A List of Stem Cell Stocks from “A” to “Z”

By 3 Comments

Biotech investing has become an increasingly popular in recent years. Whether you’re new to biotech stocks or you’ve been around the block, with the recent stock market drops caused by COVID-19, now could be a good time to place your bets.

The stock market had its largest point drop in recent history on March 9, 2020. Shortly thereafter, on March 12 and March 16, there were two more record-setting point drops. Even though the market has recovered somewhat following the $2.2 trillion stimulus bill, market prices remain attractive across many sectors.

Furthermore, stem cell companies are receiving startling support for use of living therapeutics against COVID-19 induced respiratory complications, such as ARDS. The Australian company, Mesoblast, is now enrolling for a 300 person trial and the American company, Athersys, is enrolling for an even larger 400 person trial.

Under these conditions, one of the most intriguing niches within biotech investing is stem cell stocks. [Read more…]

Mesoblast to Enroll 300 Patients in COVID-19 Trial of Stem Cell Therapy Remestemcel-L

By 1 Comment

Phase 2/3 Randomized Controlled Trial of Remestemcel-L in 300 Patients With COVID-19 Acute Respiratory Distress Syndrome Begins Enrollment

NEW YORK, April 30, 2020 — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced a Phase 2/3 randomized, placebo-controlled trial to rigorously confirm whether its allogeneic mesenchymal stem cell therapy remestemcel-L provides a survival benefit in moderate/severe acute respiratory distress syndrome (ARDS) due to COVID-19 has commenced enrollment. [Read more…]

Stem Cells for Coronavirus: Could Cells Be The Cure?

By 1 Comment

*Article Updated 05/06/20 — Coronavirus disease (COVID-19) is an emerging global pandemic that is threatening the viability of healthcare systems worldwide. The virus responsible for the disease is also known as severe acute respiratory syndrome coronavirus 2 and abbreviated as SARS-CoV-2. The eruption started in China on December 29, 2019 and by March 2020 it was reported that it had spread to several countries across the world. [Read more…]

Organicell Announces FDA Approval of IND Application for the Treatment of SARS Due to COVID-19

By 2 Comments

MIAMI, May 05, 2020 — Organicell Regenerative Medicine, Inc. (OTCBB:BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Organicell Flow, for patients diagnosed with moderate to severe acute respiratory syndrome (SARS) due to COVID-19 infection. [Read more…]

GIOSTAR Announces FDA Approval Under Compassionate Use for a COVID-19 Clinical Trial with Stem Cells

By Leave a Comment

Groundbreaking research provides a promising potential alternative to manage devastating pandemic

SAN DIEGO, May 4, 2020 — Global Institute of Stem Cell Therapy and Research (GIOSTAR), the worldwide leader in stem cell research, is pleased to announce that they have received an approval for a COVID-19 clinical trial, led by their Medical Director Dr. Prabhat Soni. GIOSTAR will conduct the trial using stem cells to treat COVID-19 patients, under the approval of the United States Food and Drug Administration (FDA) “expanded access for compassionate use” program. The Institute is exploring a promising alternative approach to the devastating disorder, which leverages the anti-inflammatory properties of mesenchymal stem cells (MSCs). According to Dr. Soni, the investigation is based upon two decades of stem cell research by GIOSTAR Co-Founder, Chairman and Chief Scientific Officer Dr. Anand Srivastava. [Read more…]

BioInformant's World-Class Clients